ASCO 2019

3 takeaways from cancer's biggest conference
3 takeaways from cancer's biggest conference
Biopharma Dive
Amgen
KRAS
accelerated approvals
Turning Point Therapeutics
Keytruda
Opdivo
ASCO 2019
Flag link:
Was ASCO 2019 'quiet'? Pharma, biotech execs weigh in
Was ASCO 2019 'quiet'? Pharma, biotech execs weigh in
Fierce Pharma
ASCO 2019
Flag link:
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
Flag link:
A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo
A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo
BioCentury
ASCO 2019
NKTR-214
Nektar Therapeutics
metastatic melanoma
Flag link:
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
Flag link:
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Novartis
ASCO 2019
Incyte
MET inhibitors
capmatinib
non-small cell lung cancer
Flag link:
3 Cancer Stocks Given a Lift by Amgen
3 Cancer Stocks Given a Lift by Amgen
Motley Fool
Amgen
KRAS
AMG 510
Mirati Therapeutics
Array Biopharma
Gilead Sciences
ASCO 2019
Flag link:
Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?
Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?
Investors Business Daily
Amgen
AMG 510
KRAS
ASCO 2019
lung cancer
colon cancer
Flag link:
ASCO 2019 – The results of clinical practices changing phase III studies
ASCO 2019 – The results of clinical practices changing phase III studies
Pharmaforum
clinical trials
ASCO 2019
Merck
AstraZeneca
Flag link:
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
Flag link:
Gilead highlights Yescarta survival data in ASCO update
Gilead highlights Yescarta survival data in ASCO update
Pharmaforum
Gilead Sciences
clinical trials
Yescarta
relapsed or refractory diffuse large B-cell lymphoma
ASCO 2019
Flag link:
ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR
ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR
Fierce Biotech
ASCO 2019
clinical trials
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
Flag link:
ASCO: With FDA review nearing, Epizyme shares updated sarcoma data
ASCO: With FDA review nearing, Epizyme shares updated sarcoma data
Fierce Biotech
ASCO 2019
Epizyme
clinical trials
tazemetostat
epithelioid sarcoma
Flag link:
Early cancer drug data give Amgen hope it's 'cracked KRAS code'
Early cancer drug data give Amgen hope it's 'cracked KRAS code'
Biopharma Dive
ASCO 2019
KRAS
lung cancer
colorectal cancer
pancreatic cancer
Amgen
AMG 510
Flag link:
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Pharmaceutical Business Review
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
Flag link:
ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win
ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win
Fierce Pharma
JNJ
Darzalex
ASCO 2019
Flag link:
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
BioCentury
Blueprint Medicines
BLU-667
ASCO 2019
Eli Lilly
RET-altered cancer
LOXO-292
Flag link:
Seattle Genetics drug could provide new option for bladder cancer patients
Seattle Genetics drug could provide new option for bladder cancer patients
Biopharma Dive
Seattle Genetics
ASCO 2019
enfortumab vedotin
urothelial cancer
Flag link:
Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Fierce Biotech
ASCO 2019
Ayala Pharmaceuticals
Novartis
triple negative breast cancer
AL101
Flag link:
#ASCO19: Sanofi sets the stage for a late arrival of their multiple myeloma drug isatuximab — with J&J and Genmab laying in wait
#ASCO19: Sanofi sets the stage for a late arrival of their multiple myeloma drug isatuximab — with J&J and Genmab laying in wait
Endpoints
Sanofi
Multiple Myeloma
isatuximab
ASCO 2019
Flag link:

Pages